mProX™ Human ROR1 Stable Cell Line

Product Information

Target Family

Other Targets

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1;KLE

Target Classification

Other Targets Drug Discovery Assays and Products

Target Research Area

CNS Research;Cardisvascular Research

Related Diseases

Deafness, Autosomal Recessive 108; Rare Autosomal Recessive Non-Syndromic Sensorineural Deafness Type Dfnb

Gene ID

Human:4919

UniProt ID

Human:Q01973

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

ROR1, a marker antigen recommended by the European Research Initiative on Chronic Lymphocytic Leukemia (CLL), is used in the assessment of measurable residual disease (MRD) in CLL patients. A new nine-color assay for CLL MRD using ROR1 has been developed, which is comparable to the standardized methods based on flow cytometry and real-time quantitative PCR. ROR1 has also been investigated as a tumor biomarker in breast cancer, showing significant correlations with other biomarkers such as HER3 and playing a role in prognosis and prediction of treatment response. Additionally, ROR1 has been targeted for the treatment of triple negative breast cancer using small molecules. In cholangiocarcinoma, ROR1-AS1, a long non-coding RNA, has been found to promote cell proliferation and invasion. Furthermore, ROR1 has been utilized in the accurate classification of childhood medulloblastoma subgroups, aiding in appropriate treatment and targeted therapies.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human ROR1 Stable Cell Line (S01YF-1023-PY285). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Peyton Jones (Verified Customer)

How does ROR1 expression affect cancer survival? Jun 10 2020

chat Patrick Liam (Creative Biolabs Scientific Support)

ROR1 expression is associated with adverse outcomes in cancer survival, highlighting its potential as a target for cancer therapeutics. Jun 10 2020

chat Alex Johnson (Verified Customer)

What is the role of ROR1 in breast cancer? Jun 01 2023

chat Patrick Liam (Creative Biolabs Scientific Support)

ROR1 is expressed in human breast cancers and is associated with enhanced tumor-cell growth, indicating its biological and clinical significance. Jun 01 2023

Published Data

Fig.1 A significant reduction in proliferation was observed in KLE cells upon knockdown of ROR1.

At the protein level in KLE cells, a reduction in ROR1 was demonstrated through representative immunoblots, with α-tubulin serving as the loading control. Subsequent to ROR1 siRNA transfection, a significant decrease in KLE cell proliferation was observed 48 hours later.

Ref: Henry, C. E., et al. "ROR1 and ROR2 play distinct and opposing roles in endometrial cancer." Gynecologic oncology 148.3 (2018): 576-584.

Pubmed: 29395309

DOI: 10.1016/j.ygyno.2018.01.025

Research Highlights

Brett, Victor-Emmanuel. et al. "Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patients." Annales de biologie clinique, 2023.
Measurable residual disease (MRD) has gained recognition as a significant factor in assessing chronic lymphocytic leukemia (CLL). Its impact on progression-free and overall survival has been established independently. Flow cytometry and real-time quantitative PCR are the standard methods employed to evaluate CLL MRD. In this study, a nine-color assay utilizing the ROR-1 marker antigen, as recommended by the European Research Initiative (ERIC) on CLL, is presented. The sensitivity of this assay is at least 10-5, providing a highly reliable tool for CLL MRD detection.
Brett, Victor-Emmanuel. et al. "Principal component analysis yields results comparable to those of an elaborate Boolean strategy: simplifying the assessment of measurable residual disease in chronic lymphocytic leukemia patients." Annales de biologie clinique, 2023.
Pubmed: 37864443 DOI: 10.1684/abc.2023.1826

Hassanzadeh Makoui, Masoud. et al. "Clinico-Pathological and Prognostic Significance of a Combination of Tumor Biomarkers in Iranian Patients With Breast Cancer." Clinical breast cancer, 2023.
Breast cancer is a prevalent form of cancer globally. It presents as a complex malignancy with diverse histopathological and biological characteristics. Molecular biomarkers are crucial in providing precise diagnosis, classification, prognosis, treatment response prediction, and cancer monitoring. The current research aims to examine the clinical and pathological relevance of two biomarkers, HER3 and ROR1, in breast cancer tissue. The findings of this study have implications for improved understanding and management of breast cancer.
Hassanzadeh Makoui, Masoud. et al. "Clinico-Pathological and Prognostic Significance of a Combination of Tumor Biomarkers in Iranian Patients With Breast Cancer." Clinical breast cancer, 2023.
Pubmed: 37863762 DOI: 10.1016/j.clbc.2023.09.013